MetaCap

Annexon (ANNX) vs Kura Oncology (KURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Annexon (ANNX) has outperformed Kura Oncology (KURA) over the past year, losing 27.4% versus a loss of 38.1%. Over five years, KURA leads with a -50.7% price change compared with -77.4% for ANNX. Kura Oncology is the larger company by market cap ($634.9 million vs $591.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANNX-27.40%KURA-38.14%
+68%+12%-44%
Nov 21, 20251 yearNov 20, 2026
ANNX-78.09%KURA-59.33%
+45%-26%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANNX versus KURA key metrics
MetricANNXKURA
Share price$3.10$6.91
Market cap$591.37M$634.88M
1-day change-9.09%-5.99%
YTD return-38.25%-33.49%
1-year return-27.40%-38.14%
5-year return-77.37%-50.66%
EPS (TTM)$-1.01$-3.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$67.48M
Revenue growth (YoY)—+25.24%
Net income (latest FY)$-206.69M$-278.67M
Operating margin—-449.94%
Net margin—-412.95%
52-week high$7.18$13.90
52-week low$3.07$6.75
Distance from 52-week high-56.82%-50.29%
Analyst consensusbuystrong_buy
Avg. price target upside+448.39%+357.60%
Average volume3.36M2.10M
Shares outstanding190.76M91.88M
Employees97260
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANNX has outperformed KURA by 10.7 percentage points over the past year.

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

About Kura Oncology

KURA stock →

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees

ANNX vs KURA FAQ

Which is bigger, Annexon or Kura Oncology?

Kura Oncology (KURA) is larger, with a market capitalization of $634.88M compared with $591.37M for Annexon (ANNX).

Which stock has performed better over the past year, ANNX or KURA?

ANNX returned -27.40% over the past 12 months, compared with -38.14% for KURA (price return, excluding dividends). Past performance does not predict future results.

Are Annexon and Kura Oncology in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons